S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 146 700 KRW -0.54% Market Closed
Market Cap: ₩3T

ST Pharm Co Ltd
Total Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

ST Pharm Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
S
ST Pharm Co Ltd
KOSDAQ:237690
Total Current Assets
₩372.7B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Total Current Assets
₩6.4T
CAGR 3-Years
0%
CAGR 5-Years
29%
CAGR 10-Years
N/A
A
ADM Korea Inc
KOSDAQ:187660
Total Current Assets
₩9.3B
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
Peptron Inc
KOSDAQ:087010
Total Current Assets
₩115.7B
CAGR 3-Years
71%
CAGR 5-Years
10%
CAGR 10-Years
23%
F
FutureChem Co Ltd
KOSDAQ:220100
Total Current Assets
₩36.8B
CAGR 3-Years
10%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Total Current Assets
₩521.4B
CAGR 3-Years
40%
CAGR 5-Years
39%
CAGR 10-Years
33%
No Stocks Found

ST Pharm Co Ltd
Glance View

Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.

Intrinsic Value
86 835.24 KRW
Overvaluation 41%
Intrinsic Value
Price ₩146 700
S

See Also

What is ST Pharm Co Ltd's Total Current Assets?
Total Current Assets
372.7B KRW

Based on the financial report for Dec 31, 2025, ST Pharm Co Ltd's Total Current Assets amounts to 372.7B KRW.

What is ST Pharm Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
10%

Over the last year, the Total Current Assets growth was 13%. The average annual Total Current Assets growth rates for ST Pharm Co Ltd have been 12% over the past three years , 10% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett